NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Income from Continuing Operations of 48441000.0 for Q1 2026, up 35.35% sequentially from 74923000.0 in Q4 2025, and down 22.55% YoY from 62546219.16 in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Income from Continuing Operations for 4 years, with the latest figure at 48441000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 22.55% year-over-year to 48441000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 212733000.0 (down 13.54% YoY) and the FY2025 annual result came in at 151234000.0, up 37.4% from the prior year.
- Income from Continuing Operations grew to 48441000.0 in Q1 2026 per NAMS's latest filing, from 74923000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16647000.0 in Q3 2024 and troughed at 93767000.0 in Q1 2024.
- A 4-year average of 51597538.46 and a median of 47133000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 64.68% in 2024, then tumbled 332.54% in 2025.
- Over 4 years, Income from Continuing Operations stood at 49468000.0 in 2023, then sank by 86.34% to 92177000.0 in 2024, then rose by 18.72% to 74923000.0 in 2025, then surged by 35.35% to 48441000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 48441000.0, 74923000.0, and 72005000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | -64.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -64.14 Mn |
| Mar 31, 2026 | -48.44 Mn |
| Dec 31, 2025 | -74.92 Mn |
| Sep 30, 2025 | -72.01 Mn |
| Jun 30, 2025 | -17.36 Mn |
| Mar 31, 2025 | -39.53 Mn |
| Dec 31, 2024 | -92.18 Mn |
| Sep 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -39.01 Mn |
| Mar 31, 2024 | -93.77 Mn |
| Dec 31, 2023 | -49.47 Mn |
| Sep 30, 2023 | -47.13 Mn |
| Jun 30, 2023 | -38.29 Mn |
| Mar 31, 2023 | -42.02 Mn |